Whether that effort is revived may depend on a potential special session. “He has kind of signaled he may do a special ...

CMS’ drug price negotiations are advancing, but new indications and exclusivity rules could complicate future pricing cycles. CMS gained the authority to negotiate list prices with drug manufacturers ...

WASHINGTON (AP) — U.S. regulators will begin offering faster reviews to new medicines that administration officials deem as ...

For decades, pharmaceutical companies have shelled out big bucks to broadcasters to place ads between segments. But a pair of policies being considered by Health and Human Services Secretary Robert F.

The FDA is launching a program to reward companies with accelerated drug review and speedy agency feedback, if their actions ...

The hearing captured the tension and complexity of reining in health care costs that are among the highest in the nation, as insurers, providers and prescription drug companies all point the ...

Items published in court news are public record. The News-Democrat publishes all misdemeanors, felonies and small claims judgments recorded in district court, as well as all civil suits recorded in ...

For Americans navigating the pharmacy counter, the price of a prescription is often just the beginning of the story. Behind ...

Elon Musk took to his social media platform X to share the results of a drug test he took on June 16 amid accusations of drug ...

Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., the maker of a new gene-editing treatment, Lilly said on Tuesday.

Procuring lifesaving drugs is a daunting challenge in many low- and middle-income countries. Essential treatments are often ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...